Abeona Therapeutics Inc. (ABEO) Fair Value 2026

ABEO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 3 models active

Value Trap Risk

WARN (47/100)

Quick Summary — As of 2026-10-07, Abeona Therapeutics Inc. (ABEO) trades at $5.01, versus a $6.97 median fair value across its 3 active models — 39.1% above the current price. QOC: 5.9/10. Value Trap Risk: 47/100 (WARN). 3/13 models active. Within that set, the Bayesian DCF component alone returns $5.78.

Key Facts

Ticker
ABEO
Price
$5.01
Quality Score
5.9/10
Value Trap Risk
47/100
Models Active
3/13
Last Updated
Strength: RCMH-DCF suggests +86.8% upside with 26% confidence
Risk: Value Trap score of 47 suggests caution despite apparent undervaluation

Is Abeona Therapeutics Inc. (ABEO) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Abeona Therapeutics Inc. (ABEO) appears undervalued as of : the median of 3 independent fair value estimates is $6.97, 39.1% above the current price of $5.01. Estimates range from $5.78 to $9.36. ABEO scores 5.9/10 on fundamental quality and 47/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. ABEO’s +39.1% gap is wider than that market norm, and the Biotechnology sector median is -61.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Abeona Therapeutics Inc. Stock in 2026? →

What Fair Value Does Each Model Give ABEO?

3 Intrinsic Value Models vs. Current Price ($5.01)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $5.78 +15.5%
Intrinsic · Medium Conviction
 $9.36 +86.8%
Relative · Medium Conviction
 $6.97 +39.1%

All Models Active

All 3 models are displayed above.

What Is ABEO's Fair Value Range?

Spread across 3 independent models · $5.78 to $9.36

CirclFi's 3 active models place Abeona Therapeutics Inc. (ABEO) between $5.78 and $9.36 per share, a spread of 51% of the median. The median of that range — $6.97 — is the fair value CirclFi publishes for ABEO, against a current price of $5.01.

Low · Bayesian DCFHigh · RCMH-DCF
$5.78median $6.97$9.36
Where the range comes from
Most bearish modelBayesian DCF$5.78
Most bullish modelRCMH-DCF$9.36
Model agreement3 bullish · 0 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on ABEO, not a CirclFi price target. How each model works →

What Is Abeona Therapeutics Inc. (ABEO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Abeona Therapeutics Inc.. Trading at $5.01 against an estimated intrinsic value of $6.97, 3 of 3 active models flag meaningful upside of +39.1% at the median. The most optimistic model, RCMH-DCF, places fair value at $9.36 (+86.8%), while Bayesian DCF — the most conservative — estimates $5.78 (+15.5%). This +71.3% gap reflects genuine analytical uncertainty about Abeona Therapeutics Inc.'s intrinsic worth.

What Do the Models Say About ABEO?

3 of 13 models are currently active for ABEO. All 3 active models suggest the stock trades below fair value. Taken together, their median fair value for ABEO is $6.97 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $5.78 on its own, implying +15.5% upside from the current price. See which stocks rank higher →

How Does ABEO Rank in Biotechnology?

Among 622 Biotechnology stocks, ABEO ranks #156 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Abeona Therapeutics Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating ABEO should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ABEO a Value Trap?

CirclFi's Value Trap algorithm assigns ABEO a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Abeona Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Abeona Therapeutics Inc.'s fundamental quality profile registers 5.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +71.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ABEO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ABEO's 3 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Abeona Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

TNXPTonix Pharmaceuticals Holding Corp.QOC 5.9OKUROnKure Therapeutics, Inc.QOC 5.9PTNPalatin Technologies, Inc.QOC 5.9RYTMRhythm Pharmaceuticals, Inc.QOC 5.9NUVBNuvation Bio Inc.QOC 6.0SLNSilence Therapeutics plcQOC 5.9IPSCCentury Therapeutics, Inc.QOC 5.0TNYATenaya Therapeutics, Inc.QOC 4.4SPRCSciSparc Ltd.QOC 1.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: TNXP · OKUR · PTN · RYTM · NUVB · SLN · IPSC · TNYA · SPRC · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ABEO?

6 companies across all industries closest to ABEO’s Quality of Company score of 5.9/10.

NEGGNewegg Commerce, Inc.QOC 5.9SBDSSolo Brands, Inc.QOC 5.9PRTSCarParts.com, Inc.QOC 5.9NXRTNexPoint Residential Trust, Inc.QOC 5.9BRNBarnwell Industries, Inc.QOC 5.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NEGG · SBDS · PRTS · NXRT · BRN · NVDA

Where Does ABEO Sit in CirclFi's Biotechnology Rankings?

ABEO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Abeona Therapeutics Inc.’s Valuation?

What is Abeona Therapeutics Inc.'s intrinsic value in 2026?

CirclFi puts Abeona Therapeutics Inc. (ABEO)'s intrinsic value at $6.97 — the median of 3 independent model estimates as of 2026-10-07, ranging from $5.78 to $9.36. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $5.78 on its own. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ABEO overvalued or undervalued right now?

At $5.01, 3 of 3 active models suggest ABEO may be undervalued, while 0 indicate potential overvaluation. The median of all 3 fair value estimates is $6.97, 39.1% above the current price of $5.01 — a consensus view that ABEO is undervalued. The assessment depends on which methodology best fits Abeona Therapeutics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.9 mean for ABEO?

Abeona Therapeutics Inc.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ABEO?

CirclFi analyzes ABEO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ABEO?

Of the 3 models currently active on ABEO, RCMH-DCF is the most bullish at $9.36 per share, and Bayesian DCF is the most bearish at $5.78. CirclFi's published fair value for ABEO is the median of that range, $6.97, not either extreme. The gap between the two ends equals 51% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is ABEO a value trap in 2026?

Abeona Therapeutics Inc.'s Value Trap score is 47/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Abeona Therapeutics Inc. (ABEO) has a median fair value of $6.97 — 39.1% above the current price of $5.01 — as of 2026-10-07.” Source: circlfi.com/stock/ABEO/ · Methodology
Primary sources for this ABEO valuation
  • Financial statements: Abeona Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000318306) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ABEO as of ; valuations recomputed .